{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 203,
  "pageCount": 415,
  "prevPage": 202,
  "nextPage": 204,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a screenshot of a video to contrast the company's public claims with the underlying data source.",
  "elementsJson": [
    "paragraph",
    "screenshot"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/203",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-203",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Soleno has a long history of making shrill and unsupported claims for the tablet.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a7-659b6eeb1f1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Source: https://www.youtube.com/watch?v=fMmS4fprBgE",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dcca4c3f-572a-412b-b216-583163d76596",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.86,
        "x": 0.07,
        "y": 0.55
      },
      "kind": "image",
      "text": "2020 conference video with CEO Bhatnagar and Jennifer Miller [minutes 4:00 to 5:00]",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d9bfbba-6e71-4450-ba4a-0ccb0005247f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.72,
        "y": 0.69
      },
      "kind": "legend",
      "text": "Comparative PK chart from poster comparing DCCR to Proglycem oral suspension",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4440bde5-44ea-49a1-95bd-7046e947ddc1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.92,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Soleno’s entire existence as a public company is predicated on the purported PK superiority of its tablet in this single poster – that is, it has a lower C-max and thus prevents C-max related adverse events, although no such adverse events are ever explained. Despite this rather narrow and flimsy PK rationale, Soleno has a long history of making shrill and unsupported claims for the tablet. For example, in a 2020 conference video with Jennifer Miller, CEO Bhatnagar references the PK chart in the poster to imply that regular diazoxide rapidly spikes to unsafe levels in the blood; that it is “nearly impossible to use” for PWS; “it has a lot more side effects”; that “you have to repeatedly dose it during the day at these high levels and put the person at significant risk...DCCR was designed to get around these problems...allows us to not only have a better safety profile but also allows us to have efficacy with doses that are half to a third of what can be used with diazoxide today.”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0181d694-02f8-418a-b248-849ce9a6a7eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“nearly impossible to use”; “it has a lot more side effects”; “you have to repeatedly dose it during the day at these high levels and put the person at significant risk...DCCR was designed to get around these problems...allows us to not only have a better safety profile but also allows us to have efficacy with doses that are half to a third of what can be used with diazoxide today.” — CEO Anish Bhatnagar",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a7-6a67cefc516b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "b40452ec-953e-4bb4-bae1-300b0d1fb851",
      "evidence": "Contrasts CEO's verbal claims with the limited scope of the cited PK chart.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}